Collaborative Insights to Solve the Puzzle of Bladder Cancer
Daniel P. Petrylak, MD
Elizabeth R. Plimack, MD, MS, FASCO
Evan Y. Yu, MD
Virtual Tumor Board: Maximizing the Potential of Immuno-Oncology in Early TNBC Through Personalized Care
Heather McArthur, MD
Margaret Gatti-Mays, MD, MPH
Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
Jaffer Ajani, MD
Effective Monitoring and Management of Adverse Effects in Metastatic ESCC
Harry Yoon, MD
Differentiating First-Line Treatment Selection: Combination Immunotherapy and Chemotherapy Regimens for Metastatic ESCC
The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
Overcoming EGFR Resistance With HER3-Directed ADCs
Helena Yu, MD
Expert Peer Discussion: Integrating Novel HER3-Directed ADCs Upon Disease Progression Following EGFR TKI and Platinum Chemotherapy
Pasi Antero Jänne, MD, PhD
HER3-Directed ADCs in the Treatment of EGFR-Mutated Advanced or Metastatic NSCLC Progressing on TKI and Platinum-Based Chemotherapy
Interprofessional Monitoring and Management of AEs With HER3-Directed ADCs
Case Application: Adverse Event Management of Patients With EGFRm Resistance Treated With Novel HER3-Directed ADCs
Biologic Rationale for Targeting HER3 and Role in EGFR Resistance
Case Application: Patients With EGFRm Resistance Post TKI and Platinum Chemotherapy
The Weight of Recurrence: Navigating Multidisciplinary Care Planning in Recurring/Metastatic Cervical Cancer
Brian Slomovitz, MD
Robert L. Coleman, MD, FACOG, FACS
Differentiating Biomarker-Driven First-Line Treatment Strategies in Metastatic Gastric/GEJ Cancers
Nataliya Uboha, MD, PhD
Bringing Treatment Into Focus: Biomarker-Driven First-Line Therapy for Metastatic Gastric/GEJ Cancers
David H. Ilson, MD, PhD
Sunnie Kim, MD
Loading...
We're glad to see you're enjoying MedEd On The Go… but how about a more personalized experience?
Press cancel to remain on MedEd On The Go. Press the link below or the continue button to keep going.